Zhanbo Qu | Medicine | Best Researcher Award

Dr. Zhanbo Qu | Medicine | Best Researcher Award

Huzhou central hospital | China

Dr. Qu Zhanbo is a dedicated medical professional at Huzhou Central Hospital, with a focus on microbiology, oncology, and gastroenterology. As a researcher, Dr. Qu has made significant contributions to the scientific community, publishing multiple papers in esteemed journals. His academic journey is marked by exceptional achievements, including being recognized as a top graduate innovative talent during his master’s studies.

Professional profile👤

ORCID

Strengths for the Awards✨

  • Research Productivity: Qu Zhanbo has published 2 SCI papers as the first author, 3 SCI papers as a total of first author, and contributed to 16 SCI papers overall. This demonstrates consistent research output and collaboration.

  • Interdisciplinary Focus: His research spans microbiology, oncology, and gastroenterology — fields with significant impact on healthcare, especially in understanding colorectal cancer risk.

  • Recognition and Innovation: Awarded as a top graduate Innovative Talent during his master’s studies, reflecting early recognition for his research potential.

  • Patent Development: Involved in the development of dissolving microneedles of Clostridium butyricum and oxaliplatin, indicating a focus on translational research and innovation.

  • Diverse Publications: Contributions to reputable journals like Aging and Disease, Aging-US, Digestion, and Microbial Biotechnology highlight his research’s acceptance in well-regarded scientific communities.

Education 🎓

Dr. Qu Zhanbo pursued his medical education with a deep interest in understanding complex diseases and their microbial interactions. His academic path laid the foundation for his subsequent research endeavors, where he explored the intersection of microbiology and oncology.

Experience 💼

Currently serving at Huzhou Central Hospital, Dr. Qu combines clinical practice with groundbreaking research. His work spans various domains, including the association of Peptostreptococcus stomatis with colorectal cancer risk. Over the years, he has authored multiple SCI papers and contributed extensively to scientific literature, showcasing his expertise and commitment to advancing medical knowledge.

Research Interests On Medicine🔬

Dr. Qu’s research interests lie at the crossroads of microbiology, oncology, and gastroenterology. His investigations delve into microbial influences on cancer development, aiming to uncover novel insights that could lead to improved diagnostic and therapeutic strategies.

Awards 🏆

Dr. Qu’s academic and research excellence have been recognized through several accolades, including being awarded as a top graduate innovative talent during his master’s studies. This honor reflects his exceptional contributions to scientific inquiry and innovation.

Publications 📖

Dr. Qu has an impressive publication record, with notable papers such as:

  1. Multiple primary malignancies and gut microbiome

    • Year: 2025

    • Authors: Yinhang Wu, Zhanbo Qu, Zheng Wu, Jing Zhuang, Yingchen Wang, Zefeng Wang, Jian Chu, Quan Qi, Shuwen Han

  2. Fecal occult blood affects intestinal microbial community structure in colorectal cancer

    • Year: 2025

    • Authors: Wu Guodong, Wu Yinhang, Wu Xinyue, Shen Hong, Chu Jian, Qu Zhanbo, Han Shuwen

  3. Aging Gut Microbiome in Healthy and Unhealthy Aging

    • Year: 2024

    • Authors: Zhanbo Qu

  4. Classification of Colorectal Cancer Subtypes Based on Endoplasmic Reticulum Stress

    • Year: 2024

    • Authors: Zhanbo Qu, Jian Chu, Yinhang Wu, Jing Zhuang, Jiang Liu, Shugao Han, Wei Wu, Shuwen Han

  5. Escherichia coli on colorectal cancer: A two‐edged sword

    • Year: 2024 (October)

    • Authors: Chu Jian, Wu Yinhang, Zhuang Jing, Qu Zhanbo, Wang Zefeng, Shuwen Han

  6. Deep learning application in prediction of cancer molecular alterations based on pathological images: a bibliographic analysis via CiteSpace

    • Year: 2024 (October)

    • Authors: Yu Xiaojian, Qu Zhanbo, Chu Jian, Wang Zefeng, Liu Jian, Liu Jin, Pan Yuefen, Han Shuwen

  7. Third-generation PacBio sequencing to explore gut bacteria and gender in colorectal cancer

    • Year: 2024 (July)

    • Authors: Sheng Yu, Jian Chu, Yinhang Wu, Jing Zhuang, Zhanbo Qu, Yifei Song, Xinyue Wu, Shuwen Han

  8. Age and aging process alter the gut microbes

    • Year: 2024 (April 8)

    • Authors: Qu Zhanbo, Zhuang Jing, Han Shugao, Wu Yinhang, Chu Jian, Yu Xiang, Zhao Feimin, Liu Jian, Wu Xinyue, Wu Wei et al.

  9. Transcriptional profile and immune infiltration in colorectal cancer reveal the significance of inducible T‐cell costimulator as a crucial immune checkpoint molecule

    • Year: 2024 (March)

    • Authors: Jian Chu, Yinghang Wu, Zhanbo Qu, Jing Zhuang, Jiang Liu, Shugao Han, Wei Wu, Shuwen Han

  10. Identification of enterotype and its predictive value for patients with colorectal cancer

  • Year: 2024 (February 27)

  • Authors: Li Qingbo, Zhuang Jing, Qu Zhanbo, Chu Jian, Song Yifei, Wu Yinhang, Han Shuwen

Conclusion 🔝

Dr. Qu Zhanbo stands out as a passionate researcher and dedicated doctor whose work bridges clinical practice and scientific exploration. His contributions to microbiology, oncology, and gastroenterology continue to shape the understanding of disease mechanisms and pave the way for future innovations in medical science.

Shanbo Ma | Pharmacology | Best Researcher Award

Dr. Shanbo Ma | Pharmacology | Best Researcher Award

Deputy Chief Pharmacist | Xijing Hospital of Air Force Medical University | China

Shanbo Ma is a dedicated researcher in the field of Chinese pharmacology, focusing on the pharmacological mechanisms and therapeutic potential of traditional Chinese medicine (TCM). With a strong academic background and extensive research experience, he has contributed significantly to the study of anti-inflammatory effects and active ingredients in TCM. His expertise spans molecular biology, cell biology, and bioinformatics, making him a key figure in integrating computational and experimental approaches to drug discovery.

Professional profile👤

Scopus

Strengths for the Awards✨

  • Strong Research Output & Impact 📚

    • Published multiple peer-reviewed articles in high-impact journals such as Frontiers in Pharmacology, Journal of Ethnopharmacology, and Journal of Biomolecular Structure & Dynamics.
    • Research spans diverse pharmacological applications, including colorectal cancer, anxiety treatment, ulcerative colitis, and depression, indicating a broad impact in Chinese pharmacology and molecular medicine.
    • Co-first and co-corresponding authorships in multiple papers highlight leadership in research projects.
  • Interdisciplinary Expertise 🔬

    • Skilled in network pharmacology, molecular docking, bioinformatics, and experimental validation, demonstrating a strong foundation in both computational and experimental pharmacology.
    • Expertise in cell biology, molecular biology, and animal experiments, which are critical for translational research in pharmacology.
  • Technical & Analytical Proficiency 💻

    • Proficient in essential research tools, including GraphPad, Cytoscape, Photoshop, SYBYL, and Image J, supporting advanced data analysis and visualization.
  • Recognition & Awards 🏆

    • Received the Outstanding Paper Award (2023) from the Chinese Pharmaceutical Society, a significant achievement showcasing research excellence.
  • Educational Background & Training 🎓

    • Holds a Ph.D. in Science of Chinese Pharmacology from Northwest University (2020–2024).
    • Completed a Master’s in Chinese Medicine from Shaanxi University of Chinese Medicine and a Bachelor’s in Pharmacology from Bengbu Medical University, providing a solid academic foundation.

🎓 Education

  • 📌 2020.09 – 2024.06 | Northwest University | Doctorate in Science of Chinese Pharmacology
  • 📌 2014.09 – 2017.07 | Shaanxi University of Chinese Medicine | Master’s in Chinese Medicine
  • 📌 2013.09 – 2017.07 | Bengbu Medical University | Bachelor’s in Pharmacology

💼 Experience

Shanbo Ma has been actively involved in pharmacological research, specializing in the bioactivity screening and mechanistic exploration of TCM. His work integrates network pharmacology, bioinformatics, and molecular docking techniques to elucidate drug mechanisms. He has also demonstrated proficiency in project design and team coordination, leading multiple research initiatives and collaborations.

🔬 Research Interests On Pharmacology

  •  Screening the pharmacological substance basis of traditional Chinese medicine
  •  Investigating the anti-inflammatory effects and mechanisms of TCM and its active ingredients
  •  Utilizing bioinformatics and network pharmacology to analyze drug-target interactions
  •  Exploring molecular docking and experimental validation methods for TCM efficacy

🏆 Awards

  • 🏅 Outstanding Paper Award, Chinese Pharmaceutical Society (2023)

📚 Publications

  • Elucidation of the mechanism of action of ailanthone in the treatment of colorectal cancer: integration of network pharmacology, bioinformatics analysis and experimental validation

    • Authors: Ma Shanbo, Guo Xiaodi, et al.
    • Publication Year: 2024
  • Glycyrrhizic acid treatment ameliorates anxiety-like behaviour via GLT1 and Per1/2-dependent pathways

    • Authors: Ma Shanbo, Chong Ye, et al.
    • Publication Year: 2024
  • Virtual screening-molecular docking-activity evaluation of Ailanthus altissima (Mill.) swingle bark in the treatment of ulcerative colitis

    • Authors: Ma Shanbo, Liu Lun, et al.
    • Publication Year: 2023
  • Investigating the mechanism of Sinisan formula in depression treatment: a comprehensive analysis using GEO datasets, network pharmacology, and molecular docking

    • Authors: Zheng Meiling, Yang, Shi Xiaopeng#, Ma Shanbo#
    • Publication Year: 2024
  • Network pharmacology and molecular docking to study the potential molecular mechanism of Qi Fu Yin for diabetic encephalopathy

    • Authors: Guo Xiaodi, Wang Feiyan, Ma Shanbo#, Shi Xiaopeng#
    • Publication Year: 2023
  • Investigation into the in vivo mechanism of diosmetin in patients with breast cancer and COVID-19 using bioinformatics

    • Authors: Wang Jin*, Ma Shanbo*, et al.
    • Publication Year: 2022

🔬 Skills

  •  Expertise in cell biology, molecular biology, and animal experiments
  •  Proficient in bioinformatics tools such as GraphPad, AI, Photoshop, ImageJ, Cytoscape, and SYBYL
  •  Strong ability to design projects independently and coordinate teamwork

🔚 Conclusion

Shanbo Ma is a passionate and accomplished researcher in Chinese pharmacology, making substantial contributions to understanding the therapeutic mechanisms of traditional medicines. His expertise in network pharmacology, molecular docking, and bioinformatics enhances his ability to uncover novel insights in drug discovery. With numerous publications and an award-winning research portfolio, he continues to drive advancements in the field of traditional medicine research.